SARS‐CoV‐2‐induced telogen effluvium: a multicentric study

Moreno‐Arrones, O.M.; Lobato‐Berezo, A.; Gomez‐Zubiaur, A.; Arias‐Santiago, S.; Saceda‐Corralo, D.; Bernardez‐Guerra, C.; Grimalt, R.; Fernandez‐Crehuet, P.; Ferrando, J.; Gil, R.; Hermosa‐Gelbard, A.; Rodrigues‐Barata, R.; Fernandez‐Nieto, D.; Merlos‐Navarro, S.; Vañó‐Galván, S.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recently linked to dermatologic manifestations and is thought to affect more severely patients with androgenetic alopecia. We designed a prospective multicentric study which enrolled patients from March to August of 2020 with acute telogen effluvium (ATE) that had a prior SARS-CoV-2 infection confirmed either by serological tests (e.g. detection of serum antibodies against the virus via enzyme-linked immunosorbent assays (ELISA)) or detection of viral RNA using real-time reverse transcription polymerase chain reaction (RT-PCR).